ARO-HSD
≈ 1 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
ARO-HSD, also known as GSK4532990, is a small interfering RNA developed for the treatment of fatty liver disease. Based on the observation that "loss-of-function HSD17β13 mutations protect against the development of chronic liver disease," the therapeutic attempts to induce this loss of function and thus improve liver disease. The therapy is developed by a partnership of GlaxoSmithKline and Arrowhead Pharmaceuticals that might be worth more than $1 billion.
ARO-HSD, also known as GSK4532990, is a small interfering RNA developed for the treatment of fatty liver disease. Based on the observation that "loss-of-function HSD17β13 mutations protect against the development of chronic liver disease," the therapeutic attempts to induce this loss of function and thus improve liver disease. The therapy is developed by a partnership of GlaxoSmithKline and Arrowhead Pharmaceuticals that might be worth more than $1 billion.
References
Text derived from https://en.wikipedia.org/w/index.php?oldid=1321467265 under CC BY-SA 4.0; modifications have been made.